Simvastatin-induced up-regulation of gap junctions composed of connexin 43 sensitize Leydig tumor cells to etoposide: An involvement of PKC pathway

Toxicology

Volumn 312, Issue 1, 2013, Pages 149-157

  Wang, Lingzhi ^a,b   Fu, Yanni ^c   Peng, Jianxin ^d   Wu, Dengpan ^a   Yu, Meiling ^e   Xu, Chengfang ^c   Wang, Qin ^a   Tao, Liang ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY   (China)

^d GUANGDONG PROVINCIAL HOSPITAL OF CHINESE MEDICINE   (China)

^e BENGBU MEDICAL COLLEGE   (China)

Author keywords

Connexin 43; Etoposide; Gap junction; PKC; Simvastatin

Indexed keywords

CONNEXIN 43; ETOPOSIDE; SERINE DERIVATIVE; SIMVASTATIN;

ANIMAL CELL; ARTICLE; CELL COMMUNICATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG SAFETY; GAP JUNCTION; LEYDIG CELL TUMOR; LIPOPHILICITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION;

12-O-TETRADECANOYLPHORBOL 13-ACETATE; 3-(N-[DIMETHYLAMINO]PROPYL-3-INDOLYL)-4-(3-INDOLYL)MALEIMIDE; CONNEXIN 43; ETOPOSIDE; GAP JUNCTION; GAP JUNCTIONAL INTERCELLULAR COMMUNICATION; GF109203X; GJIC; MLTC; MURINE LEYDIG TUMOR CELL; PKC; SIMVASTATIN; TPA;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL COMMUNICATION; CELL LINE, TUMOR; CELL SURVIVAL; CONNEXIN 43; ETOPOSIDE; GAP JUNCTIONS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LEYDIG CELL TUMOR; MICE; PROTEIN KINASE C; SIMVASTATIN; UP-REGULATION;

EID: 84884182080     PISSN: 0300483X     EISSN: 18793185     Source Type: Journal    
DOI: 10.1016/j.tox.2013.08.013     Document Type: Article

References (51)

1. Ai X., Zhao W., Pogwizd S.M. Connexin43 knockdown or overexpression modulates cell coupling in control and failing rabbit left ventricular myocytes. Cardiovasc. Res. 2010, 85:751-762.
2. Alsheikh-Ali A.A., Karas R.H. The relationship of statins to rhabdomyolysis, malignancy, and hepatic toxicity: evidence from clinical trials. Curr. Atheroscler. Rep. 2009, 11:100-104.
3. Backes J.M., Howard P.A., Ruisinger J.F., Moriarty P.M. Does simvastatin cause more myotoxicity compared with other statins?. Ann. Pharmacother. 2009, 43:2012-2020.
4. Bjornsson E., Jacobsen E.I., Kalaitzakis E. Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. J. Hepatol. 2012, 56:374-380.
5. Campbell M.J., Esserman L.J., Zhou Y., Shoemaker M., Lobo M., Borman E., Baehner F., Kumar A.S., Adduci K., Marx C., Petricoin E.F., Liotta L.A., Winters M., Benz S., Benz C.C. Breast cancer growth prevention by statins. Cancer Res. 2006, 66:8707-8714.
6. Cardaba C.M., Mueller A. Distinct modes of molecular regulation of CCL3 induced calcium flux in monocytic cells. Biochem. Pharmacol. 2009, 78:974-982.
7. 2+-calpain and caspase-3 dependent pathway. Pharmacol. Res. 2003, 48:571-578.
8. Evans M., Rees A. Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same?. Drug Saf. 2002, 25:649-663.
9. Goldberg G.S., Bechberger J.F., Naus C.C. A pre-loading method of evaluating gap junctional communication by fluorescent dye transfer. Biotechniques 1995, 18:490-497.
10. Greener I.D., Sasano T., Wan X., Igarashi T., Strom M., Rosenbaum D.S., Donahue J.K. Connexin43 gene transfer reduces ventricular tachycardia susceptibility after myocardial infarction. J. Am. Coll. Cardiol. 2012, 60:1103-1110.
11. He B., Tong X., Wang L., Wang Q., Ye H., Liu B., Hong X., Tao L., Harris A.L. Tramadol and flurbiprofen depress the cytotoxicity of cisplatin via their effects on gap junctions. Clin. Cancer Res. 2009, 15:5803-5810.
12. Hong X., Wang Q., Yang Y., Zheng S., Tong X., Zhang S., Tao L., Harris A.L. Gap junctions propagate opposite effects in normal and tumor testicular cells in response to cisplatin. Cancer Lett. 2012, 317:165-171.
13. Hwang K.E., Na K.S., Park D.S., Choi K.H., Kim B.R., Shim H., Jeong E.T., Kim H.R. Apoptotic induction by simvastatin in human lung cancer A549 cells via Akt signaling dependent down-regulation of survivin. Invest. New Drugs 2010.
14. Jensen R., Glazer P.M. Cell-interdependent cisplatin killing by Ku/DNA-dependent protein kinase signaling transduced through gap junctions. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:6134-6139.
15. Khanzada U.K., Pardo O.E., Meier C., Downward J., Seckl M.J., Arcaro A. Potent inhibition of small-cell lung cancer cell growth by simvastatin reveals selective functions of Ras isoforms in growth factor signalling. Oncogene 2006, 25:877-887.
16. Kim K.A., Park P.W., Lee O.J., Kang D.K., Park J.Y. Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects. J. Clin. Pharmacol. 2007, 47:87-93.
17. King T.J., Bertram J.S. Connexins as targets for cancer chemoprevention and chemotherapy. Biochim. Biophys. Acta 2005, 1719:146-160.
18. Kokkinos P.F., Faselis C., Myers J., Panagiotakos D., Doumas M. Interactive effects of fitness and statin treatment on mortality risk in veterans with dyslipidaemia: a cohort study. Lancet 2012.
19. Koreen I.V., Elsayed W.A., Liu Y.J., Harris A.L. Tetracycline-regulated expression enables purification and functional analysis of recombinant connexin channels from mammalian cells. Biochem. J. 2004, 383:111-119.
20. Kromer A., Moosmann B. Statin-induced liver injury involves cross-talk between cholesterol and selenoprotein biosynthetic pathways. Mol. Pharmacol. 2009, 75:1421-1429.
21. Krysko D.V., Leybaert L., Vandenabeele P., D'Herde K. Gap junctions and the propagation of cell survival and cell death signals. Apoptosis 2005, 10:459-469.
22. Kuipers H.F., Biesta P.J., Groothuis T.A., Neefjes J.J., Mommaas A.M., van den Elsen P.J. Statins affect cell-surface expression of major histocompatibility complex class II molecules by disrupting cholesterol-containing microdomains. Hum. Immunol. 2005, 66:653-665.
23. Laird D.W. Connexin phosphorylation as a regulatory event linked to gap junction internalization and degradation. Biochim. Biophys. Acta 2005, 1711:172-182.
24. Lee Y.M., Chen W.F., Chou D.S., Jayakumar T., Hou S.Y., Lee J.J., Hsiao G., Sheu J.R. Cyclic nucleotides and mitogen-activated protein kinases: regulation of simvastatin in platelet activation. J. Biomed. Sci. 2010, 17:45.
25. Leinonen P., Aaltonen V., Koskela S., Lehenkari P., Korkiamaki T., Peltonen J. Impaired gap junction formation and intercellular calcium signaling in urinary bladder cancer cells can be improved by Go6976. Cell Commun. Adhes. 2007, 14:125-136.
26. Li X., Su V., Kurata W.E., Jin C., Lau A.F. A novel connexin43-interacting protein, CIP75, which belongs to the UbL-UBA protein family, regulates the turnover of connexin43. J. Biol. Chem. 2008, 283:5748-5759.
27. Lindenthal B., Bertsch T., Fassbender K., Stroick M., Kuhl S., Lutjohann D., von Bergmann K. Influence of simvastatin, pravastatin, and BM 15.766 on neutral sterols in liver and testis of guinea pigs. Metabolism 2002, 51:492-499.
28. Locke D., Bian S., Li H., Harris A.L. Post-translational modifications of connexin26 revealed by mass spectrometry. Biochem. J. 2009, 424:385-398.
29. Locke D., Harris A.L. Connexin channels and phospholipids: association and modulation. BMC Biol. 2009, 7:52.
30. MacDonald J.S., Halleck M.M. The toxicology of HMG-CoA reductase inhibitors: prediction of human risk. Toxicol. Pathol. 2004, 32(Suppl. 2):26-41.
31. Malewicz B., Kumar V.V., Johnson R.G., Baumann W.J. Lipids in gap junction assembly and function. Lipids 1990, 25:419-427.
32. Mandal C.C., Ghosh-Choudhury N., Yoneda T., Choudhury G.G. Simvastatin prevents skeletal metastasis of breast cancer by an antagonistic interplay between p53 and CD44. J. Biol. Chem. 2011, 286:11314-11327.
33. Martirosyan A., Clendening J.W., Goard C.A., Penn L.Z. Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: potential therapeutic relevance. BMC Cancer 2010, 10:103.
34. Meyer R., Malewicz B., Baumann W.J., Johnson R.G. Increased gap junction assembly between cultured cells upon cholesterol supplementation. J. Cell Sci. 1990, 96(Pt 2):231-238.
35. Naji F., Suran D., Kanic V., Vokac D., Sabovic M. Comparison of atorvastatin and simvastatin in prevention of atrial fibrillation after successful cardioversion. Int. Heart J. 2009, 50:153-160.
36. Nielsen S.F., Nordestgaard B.G., Bojesen S.E. Statin use and reduced cancer-related mortality. N. Engl. J. Med. 2012, 367:1792-1802.
37. Park J.M., Munoz J.L., Won B.W., Bliss S.A., Greco S.J., Patel S., Kandouz M., Rameshwar P. Exogenous CXCL12 activates protein kinase C to phosphorylate connexin 43 for gap junctional intercellular communication among confluent breast cancer cells 2012, Cancer Lett.
38. Ponce J., de la Ossa N.P., Hurtado O., Millan M., Arenillas J.F., Davalos A., Gasull T. Simvastatin reduces the association of NMDA receptors to lipid rafts: a cholesterol-mediated effect in neuroprotection. Stroke 2008, 39:1269-1275.
39. Sato T., Ohkusa T., Honjo H., Suzuki S., Yoshida M.A., Ishiguro Y.S., Nakagawa H., Yamazaki M., Yano M., Kodama I., Matsuzaki M. Altered expression of connexin43 contributes to the arrhythmogenic substrate during the development of heart failure in cardiomyopathic hamster. Am. J. Physiol. Heart Circ. Physiol. 2008, 294:H1164-H1173.
40. Schmidmaier R., Baumann P., Simsek M., Dayyani F., Emmerich B., Meinhardt G. The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion-mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase. Blood 2004, 104:1825-1832.
41. Segretain D., Decrouy X., Dompierre J., Escalier D., Rahman N., Fiorini C., Mograbi B., Siffroi J.P., Huhtaniemi I., Fenichel P., Pointis G. Sequestration of connexin43 in the early endosomes: an early event of Leydig cell tumor progression. Mol. Carcinog. 2003, 38:179-187.
42. Serajuddin A.T., Ranadive S.A., Mahoney E.M. Relative lipophilicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin. J. Pharm. Sci. 1991, 80:830-834.
43. Sheu J.J., Chang L.T., Chiang C.H., Sun C.K., Chang N.K., Youssef A.A., Wu C.J., Lee F.Y., Yip H.K. Impact of diabetes on cardiomyocyte apoptosis and connexin43 gap junction integrity: role of pharmacological modulation. Int. Heart J. 2007, 48:233-245.
44. Tsai C.H., Yeh H.I., Tian T.Y., Lee Y.N., Lu C.S., Ko Y.S. Down-regulating effect of nicotine on connexin43 gap junctions in human umbilical vein endothelial cells is attenuated by statins. Eur. J. Cell Biol. 2004, 82:589-595.
45. Uzzan B., Cohen R., Nicolas P., Cucherat M., Perret G.Y. Effects of statins on bone mineral density: a meta-analysis of clinical studies. Bone 2007, 40:1581-1587.
46. van der Meij E., Koning G.G., Vriens P.W., Peeters M.F., Meijer C.A., Kortekaas K.E., Dalman R.L., van Bockel J.H., Hanemaaijer R., Kooistra T., Kleemann R., Lindeman J.H. A clinical evaluation of statin pleiotropy: statins selectively and dose-dependently reduce vascular inflammation. PLoS ONE 2013, 8:e53882.
47. Van Gelder I.C. Rhythm control for atrial fibrillation: non-channel antiarrhythmic drugs are en vogue. Cardiovasc. Res. 2007, 74:8-10.
48. Wang N., De Vuyst E., Ponsaerts R., Boengler K., Palacios-Prado N., Wauman J., Lai C.P., De Bock M., Decrock E., Bol M., Vinken M., Rogiers V., Tavernier J., Evans W.H., Naus C.C., Bukauskas F.F., Sipido K.R., Heusch G., Schulz R., Bultynck G., Leybaert L. Selective inhibition of Cx43 hemichannels by Gap19 and its impact on myocardial ischemia/reperfusion injury. Basic Res. Cardiol. 2013, 108:309.
49. Wang Q., You T., Yuan D., Han X., Hong X., He B., Wang L., Tong X., Tao L., Harris A.L. Cisplatin and oxaliplatin inhibit gap junctional communication by direct action and by reduction of connexin expression, thereby counteracting cytotoxic efficacy. J. Pharmacol. Exp. Ther. 2010, 333:903-911.
50. Willecke K., Eiberger J., Degen J., Eckardt D., Romualdi A., Guldenagel M., Deutsch U., Sohl G. Structural and functional diversity of connexin genes in the mouse and human genome. Biol. Chem. 2002, 383:725-737.
51. Zhou Q., Zhou Y., Kummerow F.A. High-dose lovastatin decreased basal prostacyclin production in cultured endothelial cells. Prostaglandins Other Lipid Mediat. 2009, 89:1-7.